SABCS 2025 Post-Conference Intelligence

The first new adjuvant endocrine treatment to improve outcomes for breast cancer in decades. Tucatinib improving outcomes in the first line HER2+ setting. First phase 3 data with SG in chemo-naive pts with HR+ MBC. And so much more. See you in a few days in San Antonio! #SABCS25 https://t.co/stViMwaBIX

33.7K impressions

Ilana Schlam

@ilanaschlam

In 2025, many important and long-awaited studies were published. I included them but kept the algorithms unchanged, as there are open questions about how these data will impact practice, particularly in early and metastatic HER2+ disease and mTNBC. @DFCI_BreastOnc #SABCS25 https://t.co/mPadDcexHi

32.2K impressions

Paolo Tarantino

@ptarantinomd

Among pts with ER+/HER2+ MBC, maintenance HP (control arm) had a PFS of: -29.1 mo in PATINA -16.3 mo in HER2CLIMB-05 The difference? In PATINA all pts also received ET (only 45% in H2C-05). Reminder that, besides fancy new drugs, ET can REALLY make a difference in this disease! https://t.co/Vfbh2VTbgq

18.2K impressions

NEJM

@nejm

Presented at #SABCS25: In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan improved invasive disease–free survival but carried a risk of interstitial lung disease. Full DESTINY-Breast05 phase 3 trial results: https://t.co/gzaCa8RKk2

17.7K impressions

Paolo Tarantino

@ptarantinomd

At #SABCS25 we’ll present Cohort C of DATO-Base, academic IST and first prospective trial of Dato-DXd in pts with LMD from HER2- MBC. LANO ORR 30%, mOS 4.7 months but >1 year in ADC-naive pts, benefit on neurological symptoms. Selected for poster display 🤷‍♂️ Join us to discuss! https://t.co/tXIYJlTacJ https://t.co/V4HriaYU5B

13.5K impressions

NEJM

@nejm

Original Article: Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer (DESTINY-Breast05 phase 3 trial) https://t.co/bSyzhAR3U8 #SABCS25 | @SABCSSanAntonio https://t.co/NxQimnFjIY

11.0K impressions

NEJM

@nejm

Presented at #SABCS25: In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan improved invasive disease–free survival but carried a risk of interstitial lung disease. Full DESTINY-Breast05 phase 3 trial results: https://t.co/gzaCa8RKk2

17.7K impressions

Paolo Tarantino

@ptarantinomd

At #SABCS25 we’ll present Cohort C of DATO-Base, academic IST and first prospective trial of Dato-DXd in pts with LMD from HER2- MBC. LANO ORR 30%, mOS 4.7 months but >1 year in ADC-naive pts, benefit on neurological symptoms. Selected for poster display 🤷‍♂️ Join us to discuss! https://t.co/tXIYJlTacJ https://t.co/V4HriaYU5B

13.5K impressions

NEJM

@nejm

Original Article: Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer (DESTINY-Breast05 phase 3 trial) https://t.co/bSyzhAR3U8 #SABCS25 | @SABCSSanAntonio https://t.co/NxQimnFjIY

11.0K impressions

Oncology Brothers

@oncbrothers

#SABCS25 Day 2 Highlights: 1. #lidERA: SERD in Adj HR+ 2. #ALLTO: Adj ET in HR+/HER2+ 3. #ASCENT07: Saci in HR+ mBC 4. #HER2Climb05: Tucatinib in 1L HER2+ mBC 5. #DB11: TDXd in NeoAdj Her2+ 6. #DB05: TDXd in Adj Her2+ @SABCSSanAn…

9.5K impressions

Hope Rugo

@hoperugo

#SABCS2025 Francois-Clement Bidard presents updated Serena-6 data. PFS2 and time to ADC/Chemo better with early switch, ctDNA mESR1 fraction decreased. Remaining question is early vs later switch with lack of xover. @OncoAlert https://t.co/JiJVsNzuRJ

7.1K impressions

Sara Tolaney

@stolaney1

ASCENT-07: sacituzumab govitecan vs TPC as 1L chemo in HR+ MBC by @jhaveri_komal median f/u 15.4 mo n=690 TPC (43% cape, 57% taxane) PFS by BICR 8.3 mo vs 8.3 mo, HR 0.85,p=.13 Inv PFS 8.4 vs 6.4 (HR 0.78) OS HR 0.72 (61% in TPC recv'd subsequent ADC) @OncoAlert #SABCS25

6.3K impressions

Ilana Schlam

@ilanaschlam

Breast cancer research highlights from 2025 🧬 A non-exhaustive overview of impactful clinical trials and liquid biopsy work presented at ESMO & SABCS. ADCs, maintenance, MRD, and molecular response continue to shape where the field is headed. Still a lot more to learn. https://t.co/SQ0tleFhAE

8.2K impressions

Sara Tolaney

@stolaney1

NSABP B-59/Gepardouze ctDNA substudy (Exact sciences assay) n=212 BL 96% MRD+ Post NAT: 9% Post surgery: 6% 30-fold increase risk of distant recurrence if MRD + post surgery 95% of pts MRD negative post surgery remain free of disease at 3 yrs @oncolaert #SABCS25

7.5K impressions

Hope Rugo

@hoperugo

#SABCS2025 Francois-Clement Bidard presents updated Serena-6 data. PFS2 and time to ADC/Chemo better with early switch, ctDNA mESR1 fraction decreased. Remaining question is early vs later switch with lack of xover. @OncoAlert https://t.co/JiJVsNzuRJ

7.1K impressions

Paolo Tarantino

@ptarantinomd

Interesting ctDNA sub-analysis from CAPItello291. Most PIK3CA/AKT/PTEN alterations are found both on tissue and ctDNA, but about 10% are found only on one of the two methods. PTEN alterations the most discordant. #SABCS25 https://t.co/DhqxbknPdh

4.4K impressions

Rebecca Shatsky, MD

@dr_rshatsky

Ok I am happy with the time to chemo data here. This is what I wanted to see. This is a big deal to my patients and something that shows a meaningful benefit in my opinion. #SERENA6 #SABCS25 #ctDNA https://t.co/HErznvkKB3

4.3K impressions

Stephanie Graff, MD, FACP, FAS

@drsgraff

In SERENA-6, mESR1 ctDNA was profoundly reduced by 8 weeks after change to camizestrant. #SABCS25 @SABCSSanAntonio @OncoAlert https://t.co/TSEHAdlvE6

2.4K impressions

Sara Tolaney

@stolaney1

Fabulous presentation by @elmayermd on TBCRC 056 Preop niraparib plus dostarlimab in gBRCAm TNBC: pCR 50%. (RCB0/1 60%) increase in TIL seen at 3 wks Baseline TIL assoc with pCR @DFCI_BreastOnc @OncoAlert #SABCS25

2.8K impressions

Sara Tolaney

@stolaney1

compass pCR TILs Overall median TILs: 10%; 47% TILs<10% TILs>10% assoc w/ improved pCR (52.1 vs 36.0%, p<0.001) Not sigs in ER-neg (but sig in both subgroups as a continuous variable) Multivariable analysis w/ HER2DX, TIL no longer sign assoc w/pCR @OncoAlert #SABCS25

1.4K impressions

Ilana Schlam

@ilanaschlam

Dr Badve presents the TIL data from EA1181|CompasHER pCR showing that TILs >10% are predictive for pCR Is it time to move TILs to clinical practice? Do we need more data? #SABCS25 https://t.co/gNNsPSQzUq

289 impressions

Luca Arecco, MD

@lucarecco

GS3-01 – #SABCS25 Is it safe for #BRCA carriers to use MHT after oophorectomy (or natural menopause)? In a matched analysis of 676 BRCA1/2 pairs, MHT actually reduced breast cancer risk in BRCA1/2 carriers! E+P combination: no increased risk @OncoAlert @SABCSSanAntonio https://t.co/emnT77VfFc

593 impressions

Yakup Ergün

@dr_yakupergun

Truly remarkable results😍 In stage I–II BRCA-associated TNBC, a chemotherapy-free regimen achieving pCR rates of 60–80%‼️ #SABCS25 https://t.co/bTwefgXovH

473 impressions

Abi Siva MD

@abisivamd

Impressive results from OlympiaN at #SABCS25 Makes you wonder how many more patients we need before this is ready to be considered standard of care. #BRCA @ASCO @OncBrothers @PTarantinoMD https://t.co/CWrLIkqykG

234 impressions

Ilana Schlam

@ilanaschlam

Breast cancer research highlights from 2025 🧬 A non-exhaustive overview of impactful clinical trials and liquid biopsy work presented at ESMO & SABCS. ADCs, maintenance, MRD, and molecular response continue to shape where the field is headed. Still a lot more to learn. https://t.co/SQ0tleFhAE

8.2K impressions

Sara Tolaney

@stolaney1

NSABP B-59/Gepardouze ctDNA substudy (Exact sciences assay) n=212 BL 96% MRD+ Post NAT: 9% Post surgery: 6% 30-fold increase risk of distant recurrence if MRD + post surgery 95% of pts MRD negative post surgery remain free of disease at 3 yrs @oncolaert #SABCS25

7.5K impressions

VJ Oncology

@vjoncology

In HER2+ #BreastCancer, combining pathologist-assessed TILs with AI-derived spatial patterns improves prediction of outcomes & benefit from dual HER2 blockade 🤖🩺 At #SABCS25, Roberto Salgado ows AI complements expert pathology in the APHINITY trial analysis. Watch:

285 impressions

SABCS 2025

Who moved the needle at SABCS 2025

Top trials discussed

What KOLs were talking about

Trials discussed at SABCS 2025

The 10 tweets that defined SABCS 2025